Bioburden Test — ISO 11737-1 · Pharmaceutical Analysis

What Is Bioburden?

The bioburden test determines the number and nature of the viable microorganism population present on the product before sterilisation. Since determining the sterilisation dose and process depends directly on bioburden, it is a fundamental input to sterilisation validation.

Purpose of Bioburden

The purpose is to produce the microbiological baseline data required for designing and verifying the sterilisation process, and to monitor the continuity of manufacturing hygiene.

Which Products Is Bioburden Applied To?

Pre-sterilisation medical devices
Implants and surgical instruments
Single-use sets
Sterile-packaging components
Wound-care products

In Which Sectors Is Bioburden Used?

Medical DeviceHealthcarePharmaceuticals

Standards Related to Bioburden

ISO 11737-1determination of microbial load in medical devices test
ISO 11135
ISO 11137-1
ISO 11137-2
USP <61>

Bioburden Conditions

Recovery: The method of removing microorganisms from the specimen (shaking, sonication, rinsing) must be validated
Recovery efficiency: How much microorganism the method recovers is determined and applied to the result as a correction factor
Culture media: Separate culture media and incubation conditions for bacterial and fungal counts

Equipment for Bioburden

Sonicator and shaker
Membrane filtration unit
Incubators
Colony counting system
Biosafety cabinet

Sample Requirements for Bioburden

Product taken from the production line, before sterilisation
The number of specimens is determined per ISO 11737-1
The sampling date, line and batch information must be recorded
Specimens must be transported under conditions that do not allow microbial growth

Duration of Bioburden

The initial study, including the recovery study, takes several weeks; routine monitoring results are obtained within days, depending on the incubation period.

Bioburden Procedure

1The recovery method is selected and its efficiency is determined.
2Specimens are taken under aseptic conditions.
3Microorganisms are removed from the product.
4The resulting liquid is inoculated into culture media or filtered.
5It is incubated at the appropriate temperature and duration.
6Colonies are counted and corrected by the recovery factor.
7The result is reported as CFU per product.

Bioburden Acceptance Criteria

The bioburden test has no acceptance limit of its own; the result is an input. The organisation defines an alert and action limit for the bioburden level used in sterilisation validation, and compares routine results against these limits.

Evaluation of Results

Results are evaluated as a trend over time. An increase in bioburden may require re-evaluation of the sterilisation dose; routine monitoring is therefore part of maintaining sterilisation validity.

Bioburden Report

Standard and method applied
Specimen description, batch and sampling date
Recovery method and efficiency factor
Culture media and incubation conditions
CFU results per product
Comparison with alert/action limits

Accreditation

EUROLAB holds internationally recognised accreditation obtained from accreditation bodies party to the IAF and ILAC multilateral recognition arrangements, under ISO/IEC 17025 for laboratory testing, ISO/IEC 17020 for inspection and surveillance, and ISO/IEC 17021-1 and ISO/IEC 17065 for system and product certification. This chain ensures the reports and certificates issued are accepted worldwide.

Whether this test can be offered within accredited scope depends on your product and the standard applied; since accreditation is method-based, the scope is confirmed in writing at the quotation stage.

Scope and authorisations

Related Regulations

MDR (EU) 2017/745
ISO 11135 / ISO 11137

Pharmaceutical Analysis — What Does This Testing Field Cover?

The section below describes the field that the Bioburden test belongs to; the conditions and acceptance criteria of this particular test are given in the sections above. The scope specific to your product is confirmed in writing at the quotation stage.

Pharmaceutical analysis determines the identity, purity, quantity and behaviour of an active substance and of the finished product. What sets this family apart is that the methods are largely defined in PHARMACOPOEIAS: the European Pharmacopoeia (Ph. Eur.) and the United States Pharmacopeia (USP) give both the method and the acceptance framework together.

The binding nature of the pharmacopoeial method shapes how the field works. In other sectors a laboratory can choose a suitable method, whereas here the method in the monograph governs; if an alternative method is to be used, its equivalence must be demonstrated. This is what makes results comparable worldwide.

Analyses are carried out in several groups. Identity and assay (HPLC, UV, titration) show what the product is and how much active substance it contains. The impurity profile and residual solvents look for unwanted compounds arising from the manufacturing process. Elemental impurities address metals originating from catalysts and equipment. Dissolution and disintegration behaviour is the most important in vitro indicator of how the drug will be released in the body.

The DISSOLUTION TEST is one of the most critical measurements in the field. It is not enough for a tablet to contain the right amount of active substance; that substance must dissolve at a suitable rate. The dissolution profile is used to assess the effect of formulation changes on bioavailability and holds a central place in generic drug licensing.

METHOD VALIDATION is a mandatory step in this family. If a pharmacopoeial method is used, it is verified that the method works properly under that laboratory's conditions. If an in-house method has been developed, it is validated against parameters such as linearity, precision, accuracy, specificity, limits of detection and quantification, and robustness. A result produced with an unvalidated method cannot be used in a licence dossier.

Stability studies determine shelf life and are the longest-running work in the field. The product is held under defined temperature and humidity conditions, analysed at set intervals, and the results become the basis of the shelf life and storage condition claims. Accelerated conditions give preliminary information but real-time data is what counts.

The microbiological side is a separate body of work: microbial enumeration, testing for specified microorganisms, sterility testing for sterile products and the bacterial endotoxin test. For sterile products, packaging integrity and sterilisation validation also come into play.

Data integrity has moved to the centre of inspections in recent years. It is not enough for the result to be correct; the raw data must be traceable, unalterable and auditable. Validation of electronic record systems has therefore become an inseparable part of analysis.

Method groups in this field

Identity and assay
HPLC, UPLC, UV-Vis spectrophotometry, titration, identity confirmation by FTIR.
Impurities and residues
Related impurities, degradation products, residual solvents (GC headspace), nitrosamine screening.
Elemental impurities
Determination of elemental impurities by ICP-MS and ICP-OES and the associated risk assessment.
Physicochemical
Dissolution and disintegration, hardness, friability, uniformity of dosage units, water content (Karl Fischer), particle size.
Microbiological
Microbial enumeration, specified microorganisms, sterility, bacterial endotoxin, preservative efficacy.
Stability
Real-time and accelerated stability studies; photostability and in-use stability.

Commonly confused in this field

The pharmacopoeial method is binding; an alternative method may be used only by demonstrating its equivalence.
A result produced without method validation cannot be used in a licence dossier.
Accelerated stability does not replace real-time data; shelf life is supported by real-time results.
The dissolution profile is sensitive to apparatus type, agitation rate and medium; the conditions must be complete in the report.
A shortcoming in data integrity produces a non-conformity in an inspection even when the result is correct.
A change of formulation or supplier requires analytical comparison and, where necessary, a new stability study.

Which decisions these results support

The licence dossier and batch release
Determining shelf life and storage conditions
Method transfer and method validation
Incoming raw material acceptance control from suppliers
Assessing the effect of a formulation change on bioequivalence

Related Tests

Frequently Asked Questions About Bioburden

Why does bioburden affect the sterilisation dose?

Sterilisation reduces the microorganism count logarithmically. The higher the initial microorganism count, the higher the dose or longer the time needed to reach the same sterility assurance level (SAL). Bioburden is therefore a direct input to dose determination.

Why is recovery efficiency measured?

Not all microorganisms can be removed from the product. If the efficiency factor is not known, the true bioburden appears lower than it is, and the sterilisation dose is determined as inadequate; this is a direct safety risk.